<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04847193</url>
  </required_header>
  <id_info>
    <org_study_id>UVienna19a</org_study_id>
    <nct_id>NCT04847193</nct_id>
  </id_info>
  <brief_title>Hop Compounds and Immune System</brief_title>
  <acronym>HI</acronym>
  <official_title>Effect of Iso-alpha-Acids and Xanthohumol on Inflammatory Processes in Human</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Vienna</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to determine the effect of Xanthohumol and Iso-alpha-acids&#xD;
      from hops on the immune response of healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this placebo-controlled crossover study a study drink enriched with either a placebo,&#xD;
      Xanthohumol, Iso-alpha Acids or a combination of latter is given to the participants. A&#xD;
      washout phase before intervention and between each intervention is introduced. On day one of&#xD;
      each intervention blood is drawn in fasted state from each participant. Subsequently the&#xD;
      study drink combined with a standardized breakfast is given to the participants following a&#xD;
      second blood drawing one hour after the consumption of the study drink. On the last day of&#xD;
      each intervention blood is taken from study participants in the same manner as on day one. To&#xD;
      assess the effect of Xanthohumol and Iso-alpha acids or a combination of both, clinical&#xD;
      chemical parameters e.g. ALT, AST, Î³-GT, blood lipids (triglycerides, total cholesterol, HDL,&#xD;
      LDL), blood glucose, uric acid and CRP are determined. Furthermore, PBMC's isolated from&#xD;
      blood samples of each time point were stimulated for either 24 or 48 h. Protein levels and&#xD;
      mRNA expression of markers of inflammation is measured in PBMC's and supernatant of&#xD;
      stimulated cells.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 13, 2019</start_date>
  <completion_date type="Actual">January 27, 2021</completion_date>
  <primary_completion_date type="Actual">January 27, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in parameters of immune response</measure>
    <time_frame>5 days</time_frame>
    <description>Parameters of immune response are measured in cell culture supernatant of stimulated cells</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Inflammatory Response</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a study drink supplemented with a placebo over a time period of 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xanthohumol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a study drink supplemented with Xanthohumol over a time period of 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iso-alpha acids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a study drink supplemented with Iso-alpha acids over a time period of 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xanthohumol/Iso-alpha acids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a study drink supplemented with a combination of Xanthohumol and Iso-alpha acids over a time period of 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dietary Intervention 1: Placebo</intervention_name>
    <description>Participants receive a study drink supplemented with a placebo for 5 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dietary Intervention 2: Xanthohumol and Iso-alpha acids</intervention_name>
    <description>Participants receive a study drink supplemented with xanthohumol, Iso-alpha acids or a combination of both for 5 days</description>
    <arm_group_label>Iso-alpha acids</arm_group_label>
    <arm_group_label>Xanthohumol</arm_group_label>
    <arm_group_label>Xanthohumol/Iso-alpha acids</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy, normal weight,&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  food intolerances, food allergies, chronic inflammatory diseases, metabolic diseases,&#xD;
             viral or bacterial infections within the last 3 weeks of inclusion, intake of&#xD;
             immunosupressive medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Vienna</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Ina Bergheim</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Xanthohumol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

